| Wall Street Analysts Think Zoetis (ZTS) Could Surge 26.18%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-05-16 15:01:09 |
Czytaj oryginał (ang.) |
| Zoetis to Participate in Upcoming Investor Conferences |
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences. BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m. CT Investors and other interested parties can access live audio webcasts of the presentations by visiting http://invest. |
businesswire.com |
2025-05-15 12:30:00 |
Czytaj oryginał (ang.) |
| Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services |
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades. |
youtube.com |
2025-05-09 17:41:44 |
Czytaj oryginał (ang.) |
| Zoetis' Q1: Market Overreaction Or Justified Drop? |
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry. |
seekingalpha.com |
2025-05-09 16:16:23 |
Czytaj oryginał (ang.) |
| Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade) |
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company reported $1.48 EPS, beating estimates, with 9% organic growth despite foreign exchange headwinds; US dollar weakness should boost future results. Zoetis maintains a strong balance sheet, with $1.7 billion cash and $6.6 billion debt, supporting shareholder returns through buybacks and dividends. |
seekingalpha.com |
2025-05-08 19:56:33 |
Czytaj oryginał (ang.) |
| Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck |
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more. |
youtube.com |
2025-05-06 21:36:14 |
Czytaj oryginał (ang.) |
| Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript |
Zoetis Inc. (NYSE:ZTS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Chris Schott - JPMorgan Navann Ty - BNP Paribas Daniel Clark - Leerink Partners Operator Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. |
seekingalpha.com |
2025-05-06 16:48:47 |
Czytaj oryginał (ang.) |
| Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised |
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance. |
zacks.com |
2025-05-06 16:11:08 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-06 14:35:50 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates |
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.38 per share a year ago. |
zacks.com |
2025-05-06 13:15:51 |
Czytaj oryginał (ang.) |
| Zoetis raises forecast for 2025 revenue, profit on weaker US dollar |
Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U.S. dollar. |
reuters.com |
2025-05-06 12:31:57 |
Czytaj oryginał (ang.) |
| Zoetis Announces First Quarter 2025 Results |
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased 9% compared with the first quarter of 2024. Net income for the first quarter of 2025 was $631 million, or $1.41 per. |
businesswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Zoetis: Unleashing Margin Expansion; Initiate Strong Buy |
We initiate coverage on Zoetis with a Strong Buy rating and a $219.26 price target, driven by explosive growth in companion animal products and structural margin expansion. Zoetis's leadership in companion animal therapeutics, particularly with Librela and Simparica, supports our above-consensus EPS forecasts of $6.12 for FY25 and $6.80 for FY26. The divestiture of lower-margin feed additives enables strategic R&D reinvestment, bolstering innovation and operational growth, while maintaining competitive moats in key markets. |
seekingalpha.com |
2025-05-04 12:53:53 |
Czytaj oryginał (ang.) |
| MKKGY vs. ZTS: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Merck KGaA (MKKGY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-05-01 16:45:50 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates |
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-05-01 14:20:55 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:48 |
Czytaj oryginał (ang.) |
| Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect |
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments. |
zacks.com |
2025-04-28 14:05:35 |
Czytaj oryginał (ang.) |
| 4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off |
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong underlying operations and are generally more resilient than their non-dividend-paying counterparts. |
fool.com |
2025-04-26 22:05:00 |
Czytaj oryginał (ang.) |
| 1 Superstar Dividend Growth Stock to Buy if the Market Crashes |
The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed outright, it has experienced multiple sessions of sharp losses, as well as dramatic rebounds. |
fool.com |
2025-04-26 18:32:00 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Advances But Underperforms Market: Key Facts |
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day. |
zacks.com |
2025-04-24 23:20:32 |
Czytaj oryginał (ang.) |
| A Once-in-a-Decade Opportunity: 1 Magnificent S&P 500 Dividend Stock Down 36% to Double Up on Right Now |
It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (ZTS 1.93%). |
fool.com |
2025-02-23 10:00:00 |
Czytaj oryginał (ang.) |
| Zoetis CEO on bird flu vaccine |
Zoetis received a conditional license for its bird flu vaccine from the US Department of Agriculture to help fight the spread of the disease on poultry farms. Here's what CEO Kristin Peck had to say |
youtube.com |
2025-02-18 14:25:58 |
Czytaj oryginał (ang.) |
| Why Zoetis Stock Took Another Tumble Today |
One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (ZTS -4.49%) shares again tumbled. As of late-session trading on Friday, they were down by 4%, in no small part due to several analyst price target cuts. |
fool.com |
2025-02-14 19:15:07 |
Czytaj oryginał (ang.) |
| US grants conditional clearance to Zoetis' bird flu vaccine for poultry |
Zoetis said on Friday its bird flu vaccine has received the U.S. Department of Agriculture's conditional license for use in poultry. |
reuters.com |
2025-02-14 15:16:55 |
Czytaj oryginał (ang.) |
| Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus |
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #HPAI--Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data. Zoetis is committed to supporting poultry producers with scientif. |
businesswire.com |
2025-02-14 15:00:00 |
Czytaj oryginał (ang.) |
| Zoetis CEO says Avian Flu vaccine for poultry gets USDA approval |
Zoetis CEO Kristin Peck joins 'Closing Bell Overtime' to talk its Avian Flu vaccine, the impact of tariffs, and more. |
youtube.com |
2025-02-13 19:12:07 |
Czytaj oryginał (ang.) |
| Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity |
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share. |
seekingalpha.com |
2025-02-13 18:43:15 |
Czytaj oryginał (ang.) |
| Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates |
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook. |
zacks.com |
2025-02-13 14:31:31 |
Czytaj oryginał (ang.) |
| Zoetis Inc. (ZTS) Q4 2024 Earnings Call Transcript |
Zoetis Inc. (NYSE:ZTS ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Steve Frank - IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Russell Yuen - William Blair Balaji Prasad - Barclays Chris Schott - JPMorgan Glen Santangelo - Jefferies Navann Ty - BNP Paribas Chris LoBianco - TD Securities Andrea Alfonso - UBS Daniel Clark - Leerink Partners Operator Welcome to the Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis. |
seekingalpha.com |
2025-02-13 14:27:41 |
Czytaj oryginał (ang.) |
| Why Zoetis Stock Was Falling Today |
Shares of Zoetis (ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter. |
fool.com |
2025-02-13 14:24:53 |
Czytaj oryginał (ang.) |
| Zoetis Earnings Top Analysts' Forecasts |
Zoetis (ZTS -8.79%), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded the consensus estimate of $1.36. |
fool.com |
2025-02-13 12:49:25 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-13 12:36:19 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Tops Q4 Earnings and Revenue Estimates |
Zoetis (ZTS) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.24 per share a year ago. |
zacks.com |
2025-02-13 11:10:28 |
Czytaj oryginał (ang.) |
| Zoetis forecasts 2025 profit, revenue below estimates; shares fall |
Animal healthcare company Zoetis forecast annual profit and revenue below Wall Street estimates on Thursday, partly due to a hit from a stronger dollar, sending its shares down 9% in premarket trading. |
reuters.com |
2025-02-13 10:47:17 |
Czytaj oryginał (ang.) |
| Phibro Animal Health Is Cruising With Its Recent Zoetis Acquisition |
Phibro Animal Health delivers animal health and nutritional solutions through feed additives, vaccines, and performance products. The Zoetis acquisition added 37 product lines, driving a 24% increase in net sales and 64% growth in adjusted EBITDA. The company projects strong revenue growth in 2025 with expanding margins and updated EPS guidance. |
seekingalpha.com |
2025-02-13 10:15:00 |
Czytaj oryginał (ang.) |
| Zoetis Reports Fourth Quarter and Full Year 2024 Results |
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter of 2024 increased 6% compared with the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $581 mill. |
businesswire.com |
2025-02-13 09:00:00 |
Czytaj oryginał (ang.) |
| Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zoetis (ZTS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. |
zacks.com |
2025-02-10 12:20:46 |
Czytaj oryginał (ang.) |
| Looking to Grow Your Passive Income in 2025? 3 Top Dividend Growth Stocks to Double Up On Right Now |
There's no way around it. I'm approaching the age of 40 faster than I'd like. |
fool.com |
2025-02-08 11:23:00 |
Czytaj oryginał (ang.) |
| UTHR or ZTS: Which Is the Better Value Stock Right Now? |
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2025-02-07 14:41:21 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-02-07 11:50:21 |
Czytaj oryginał (ang.) |
| My Top 15 High Growth Dividend Stocks For January 2025 |
The SPDR S&P 500 ETF Trust ended 2024 on a sour note, losing 2.41% in December and finishing the year up 24.89%. The Top 15 dividend growth stocks for January 2025 offer an average dividend yield of 1.21% and appear to be about 27% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.33% compound annual growth rate. |
seekingalpha.com |
2025-01-03 00:49:14 |
Czytaj oryginał (ang.) |
| Dividends Matter - 3 Of My Favorite Stocks In An Overpriced Market |
The market's lofty valuations make finding value tricky, but dividend stocks remain a beacon of stability and growth for long-term investors. I've identified three standout dividend stocks offering solid fundamentals, attractive yields, and resilience in today's overpriced market. These picks balance income and growth, making them ideal for navigating challenging conditions while building wealth over time. |
seekingalpha.com |
2025-01-01 09:30:00 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) is a Top-Ranked Growth Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-30 12:46:14 |
Czytaj oryginał (ang.) |
| The Wall Street Journal Vs. Zoetis |
The Wall Street Journal released an article claiming that Zoetis' OA pain drug (Librela) is not safe. I go over these claims and explain why I believe they are unfounded. Librela might face a label change soon, but I don't think there's any reason to worry. I explain why. |
seekingalpha.com |
2024-12-26 12:32:29 |
Czytaj oryginał (ang.) |
| Here's Why Zoetis (ZTS) Gained But Lagged the Market Today |
Zoetis (ZTS) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session. |
zacks.com |
2024-12-20 21:16:11 |
Czytaj oryginał (ang.) |
| SDZNY or ZTS: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2024-12-20 14:41:11 |
Czytaj oryginał (ang.) |
| 5 Magnificent Dividend Growth Stocks Down 24% to 41% to Buy Before 2025 for a Lifetime of Passive Income |
If you're an investor looking to grow your long-term passive income prospects, the five stocks in this article could be perfect to add to your portfolio before 2025. |
fool.com |
2024-12-19 06:45:00 |
Czytaj oryginał (ang.) |
| 4 Stocks in Focus That Declared Dividend Hikes Amid Market Volatility |
Stocks like PCAR, ZTS, AVGO and TGLS recently announced dividend hikes. |
zacks.com |
2024-12-16 13:40:21 |
Czytaj oryginał (ang.) |
| Here's Why Zoetis (ZTS) is a Strong Growth Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-13 12:46:34 |
Czytaj oryginał (ang.) |
| A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025 |
One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities. |
fool.com |
2024-12-13 10:45:00 |
Czytaj oryginał (ang.) |
| Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase |
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 21, 2025. “Zoetis' performance has been strong this year, driven by our diverse, science-driven portfolio and our diffe. |
businesswire.com |
2024-12-12 18:15:00 |
Czytaj oryginał (ang.) |
| The animal health industry is resilient, Zoetis CEO |
Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.' |
youtube.com |
2024-12-05 07:00:14 |
Czytaj oryginał (ang.) |
| SDZNY vs. ZTS: Which Stock Is the Better Value Option? |
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-04 14:46:35 |
Czytaj oryginał (ang.) |
| Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue? |
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-04 14:36:16 |
Czytaj oryginał (ang.) |
| My Top 15 High-Growth Dividend Stocks For December 2024 |
The SPDR S&P 500 ETF Trust posted a strong gain of 5.96% in November, resuming its strong run in 2024. The Top 15 dividend growth stocks for December 2024 offer an average dividend yield of 1.2% and appear to be about 22% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 12.41% compound annual growth rate. |
seekingalpha.com |
2024-12-02 08:00:00 |
Czytaj oryginał (ang.) |
| Zoetis: Healing Paws, Growing Profits |
Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Librela, Solensia and Simparica Trio will drive the stock going forward. |
seekingalpha.com |
2024-11-29 11:03:49 |
Czytaj oryginał (ang.) |
| Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-27 12:46:10 |
Czytaj oryginał (ang.) |
| Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript) |
Zoetis Inc. (NYSE:ZTS ) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation. |
seekingalpha.com |
2024-11-20 19:34:32 |
Czytaj oryginał (ang.) |
| SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now? |
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now? |
zacks.com |
2024-11-18 14:41:10 |
Czytaj oryginał (ang.) |
| Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy |
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment. |
seekingalpha.com |
2024-11-18 06:16:12 |
Czytaj oryginał (ang.) |